ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
혈관성 치매 시장 규모는 향후 수년간 빠르게 성장할 것으로 예상되며, 2029년까지 연평균 11.8%의 연평균 복합 성장률(CAGR)로 51억 1,000만 달러에 달할 것으로 예측됩니다. 예측 기간 중 예상되는 성장의 원동력은 혈관성 치매에 대한 인식 증가, 헬스케어 투자 증가, 고령화, 심혈관 질환의 유병률 증가, 고혈압 유병률 증가입니다. 예측 기간 중 주요 동향으로는 기술 발전, 개인별 맞춤 치료 계획, 원격의료, 유전자 치료, 인공지능의 통합 등이 있습니다.
심혈관 질환의 유병률 증가는 혈관성 치매 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환에는 관상동맥질환, 심부전, 부정맥, 고혈압 등 심장과 혈관에 영향을 미치는 다양한 장애가 포함됩니다. 건강에 해로운 생활습관, 불규칙한 식습관, 운동 부족, 스트레스 증가, 인구 고령화, 비만, 당뇨병, 고혈압 등 위험인자 증가 등의 요인이 심혈관 질환 증가에 기여하고 있습니다. 이러한 질환은 뇌로 가는 혈류를 방해하여 혈관성 치매의 위험을 높이고, 산소 및 영양소 부족으로 인한 인지기능 저하와 뇌세포 손상을 유발할 수 있습니다. 예를 들어 2024년 9월 영국 심장재단에 따르면 영국에서는 약 760만 명이 심장 및 순환기계 질환을 앓고 있으며, 남성 약 400만 명, 여성 약 360만 명이 이 질환을 앓고 있습니다. 이들 질환은 영국 전체 사망의 27%를 차지하며, 연간 총 17만 명 이상, 하루 약 480명이 사망하고 있습니다. 결과적으로 심혈관 질환의 유병률 증가가 혈관성 치매 시장의 성장을 주도하고 있습니다.
혈관성 치매 시장의 업체들은 경쟁력을 유지하기 위해 멀티모달 요법과 같은 새로운 치료법 개발에 주력하고 있습니다. 멀티모달 치료는 약물 치료, 물리치료, 심리학적 개입 등 다양한 치료 접근법을 결합하여 종합적인 치료를 제공하는 것입니다. 예를 들어 2023년 1월 싱가포르에 본사를 둔 바이오 제약사 모리아크(Moriac)는 치료 옵션이 적은 혈관성 치매(VaD)에 특화된 증거 기반 치료제 CognivAiD를 출시했습니다. CognivAiD는 혈관성 치매 환자의 인지기능 저하를 지연시키는 것으로 입증된 은행나무, 인삼, 사프란의 활성 추출물을 함유하고 있으며, 혈관성 치매의 주요 기전인 혈관 보호, 혈관 조절, 신경 염증에 대한 복합적인 작용을 통해 혈관성 치매의 주요 기전에 대응합니다. CognivAiD는 광범위한 임상시험과 강력한 안전성 프로파일을 바탕으로 혈관성 치매 환자를 위한 유망한 새로운 치료법입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 혈관성 치매PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 혈관성 치매 시장 : 성장률 분석
세계의 혈관성 치매 시장 실적 : 규모와 성장, 2019-2024
세계의 혈관성 치매 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 혈관성 치매 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 혈관성 치매 시장 : 제품별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
모노클로널 항체
소분자
펩티드
세계의 혈관성 치매 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 혈관성 치매 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원과 진료소
재활 센터
전문 클리닉
세계의 혈관성 치매 시장, 모노클로널 항체의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항아밀로이드 모노클로널 항체
항타우 모노클로널 항체
세계의 혈관성 치매 시장, 소분자의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
콜린에스테라아제 저해제
글루타민산 모듈레이터
항염증성 소분자
세계의 혈관성 치매 시장, 펩티드의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
아밀로이드 β표적 펩티드
신경 보호 펩티드
타우 표적 펩티드
제7장 지역별·국가별 분석
세계의 혈관성 치매 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 혈관성 치매 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
혈관성 치매 시장 : 경쟁 구도
혈관성 치매 시장 : 기업 개요
Intermountain Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis
CSPC Ouyi Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
Duke Health Overview, Products and Services, Strategy and Financial Analysis
Massachusetts General Hospital Overview, Products and Services, Strategy and Financial Analysis
Emory Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Apollo Hospitals Enterprise Limited
Amedisys Inc.
Northwestern Memorial HealthCare
IBS Hospitals Pvt. Ltd.
Resverlogix Corp.
ProNeurogen Inc.
Cyclerion Therapeutics Inc.
Aribio Inc.
Pinteon Therapeutics Inc.
Dementech Neurosciences Ltd.
Moleac Pte. Ltd.
Isaac Health Inc.
Cadabam's Group of Hospitals
Alpha Cognition Inc.
Citi Health
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
혈관성 치매 시장 2029 : 새로운 기회를 제공하는 국가
혈관성 치매 시장 2029 : 새로운 기회를 제공하는 부문
혈관성 치매 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
Vascular dementia is a form of cognitive decline caused by reduced blood flow to the brain, often resulting from strokes or other vascular issues. This condition leads to memory loss and impaired thinking. Treatment for vascular dementia primarily focuses on managing underlying vascular conditions, such as controlling high blood pressure, diabetes, and cholesterol, along with promoting a healthy lifestyle to enhance brain health and slow the disease's progression.
Key products in the treatment of vascular dementia include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies are designed to target specific proteins or molecules related to the disease. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are intended for use in hospitals, clinics, rehabilitation centers, and specialty clinics.
The vascular dementia market research report is one of a series of new reports from The Business Research Company that provides vascular dementia market statistics, including vascular dementia industry global market size, regional shares, competitors with a vascular dementia market share, detailed vascular dementia market segments, market trends and opportunities, and any further data you may need to thrive in the vascular dementia industry. This vascular dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vascular dementia market size has grown rapidly in recent years. It will grow from $2.92 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth during the historical period can be attributed to higher healthcare spending, an increase in the number of patients diagnosed with vascular dementia, a rise in healthcare professionals, the expansion of public health initiatives, and a growing prevalence of diabetes.
The vascular dementia market size is expected to see rapid growth in the next few years. It will grow to $5.11 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The expected growth in the forecast period is driven by a greater awareness of vascular dementia, rising healthcare investments, an aging population, a higher incidence of cardiovascular diseases, and an increase in the prevalence of high blood pressure. Key trends in the forecast period include technological advancements, personalized care plans, telemedicine, gene therapy, and the integration of artificial intelligence.
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the vascular dementia market. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, arrhythmias, and hypertension. Factors such as unhealthy lifestyles, poor dietary habits, physical inactivity, heightened stress levels, aging populations, and an increase in risk factors such as obesity, diabetes, and hypertension are contributing to the rise in cardiovascular diseases. These conditions increase the risk of vascular dementia by disrupting blood flow to the brain, which can lead to cognitive decline and brain cell damage due to insufficient oxygen and nutrients. For example, according to the British Heart Foundation in September 2024, approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with around 4 million men and 3.6 million women living with these conditions. These diseases are responsible for 27% of all deaths in the UK, totaling over 170,000 deaths annually, or about 480 deaths per day. As a result, the increasing prevalence of cardiovascular diseases is driving the growth of the vascular dementia market.
Companies in the vascular dementia market are focusing on developing new therapies, such as multimodal therapies, to maintain their competitive edge. Multimodal therapies combine various treatment approaches, including medications, physical therapy, and psychological interventions, to provide comprehensive treatment. For example, in January 2023, Moleac, a biopharmaceutical company based in Singapore, launched CognivAiD, an evidence-based treatment specifically designed for vascular dementia (VaD), a condition with few therapeutic options. This product combines active extracts from ginkgo, ginseng, and saffron, which have been shown to slow cognitive decline in VaD patients. The multimodal action of CognivAiD addresses key mechanisms of vascular dementia, such as vascular protection, vasoregulation, and neuroinflammation. Supported by extensive clinical trials and a strong safety profile, CognivAiD offers a promising new treatment for individuals with VaD.
In November 2023, Merck, a US-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undisclosed amount. This acquisition is intended to accelerate the development of small-molecule therapeutics targeting neurodegenerative diseases, including Parkinson's disease and dementia. Caraway Therapeutics Inc. is a biopharmaceutical company based in the US, specializing in drug discovery and development for dementia.
Major players in the vascular dementia market are Intermountain Healthcare Inc., CSPC Ouyi Pharmaceutical Co. Ltd., Duke Health, Massachusetts General Hospital, Emory Healthcare Inc., Apollo Hospitals Enterprise Limited, Amedisys Inc., Northwestern Memorial HealthCare, IBS Hospitals Pvt. Ltd., Resverlogix Corp., ProNeurogen Inc., Cyclerion Therapeutics Inc., Aribio Inc., Pinteon Therapeutics Inc., Dementech Neurosciences Ltd., Moleac Pte. Ltd., Isaac Health Inc., Cadabam's Group of Hospitals, Alpha Cognition Inc., and Citi Health.
North America was the largest region in the vascular dementia market in 2024. The regions covered in vascular dementia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vascular dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vascular dementia market consists of revenues earned by entities providing services such as diagnosis, treatment, care management, and support for individuals. The market value includes the value of related goods sold by the service provider or included within the service offering. The vascular dementia market includes sales of assistive devices, cognitive enhancers, and diagnostic tools. Values in this market are 'factory gate' values, meaning the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including healthcare providers, wholesalers, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vascular Dementia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vascular dementia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vascular dementia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vascular dementia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product: Monoclonal Antibodies; Small Molecules; Peptides
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) By End User: Hospitals And Clinics; Rehabilitation Centers; Specialty Clinics
Subsegments:
1) By Monoclonal Antibodies: Anti-Amyloid Monoclonal Antibodies; Anti-Tau Monoclonal Antibodies
2) By Small Molecules: Cholinesterase Inhibitors; Glutamate Modulators; Anti-Inflammatory Small Molecules
3) By Peptides: Amyloid-Beta Targeted Peptides; Neuroprotective Peptides; Tau-Targeting Peptides
Companies Mentioned: Intermountain Healthcare Inc.; CSPC Ouyi Pharmaceutical Co. Ltd.; Duke Health; Massachusetts General Hospital; Emory Healthcare Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vascular Dementia Market Characteristics
3. Vascular Dementia Market Trends And Strategies
4. Vascular Dementia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Vascular Dementia Growth Analysis And Strategic Analysis Framework
5.1. Global Vascular Dementia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Vascular Dementia Market Growth Rate Analysis
5.4. Global Vascular Dementia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Vascular Dementia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Vascular Dementia Total Addressable Market (TAM)
6. Vascular Dementia Market Segmentation
6.1. Global Vascular Dementia Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Small Molecules
Peptides
6.2. Global Vascular Dementia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.3. Global Vascular Dementia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Rehabilitation Centres
Speciality Clinics
6.4. Global Vascular Dementia Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Amyloid Monoclonal Antibodies
Anti-Tau Monoclonal Antibodies
6.5. Global Vascular Dementia Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cholinesterase Inhibitors
Glutamate Modulators
Anti-Inflammatory Small Molecules
6.6. Global Vascular Dementia Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amyloid-Beta Targeted Peptides
Neuroprotective Peptides
Tau-Targeting Peptides
7. Vascular Dementia Market Regional And Country Analysis
7.1. Global Vascular Dementia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Vascular Dementia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
